ArticleCureus2025
Incidence and Outcomes of Neutropenic Enterocolitis Post-stem Cell Transplant for Hematological Malignancies: A Retrospective Study in Australia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutropenic enterocolitis (NE) is a well-known occurrence in patients who receive chemotherapy and stem cell transplantation for hematological malignancies. Nonetheless, there is a lack of Australian research data available on this life-threatening condition. The purpose of this study is to determine the percentage of patients with multiple myeloma and lymphoma who develop NE after autologous stem cell transplant (ASCT) in an Australian setting and to examine the mortality rates in the selected group. Retrospective data were collected from a small pilot group of patients (N = 33) at a private hospital in Melbourne, Australia, who underwent ASCT between February 2023 and December 2024 for multiple myeloma and lymphoma. Patients received either carmustine, etoposide, cytarabine, and melphalan (BEAM); melphalan; or thiotepa, busulfan, and cyclophosphamide (TBC) as conditioning chemotherapy. Patients were then transplanted with peripherally collected CD34+ (positive) cells. Results indicate that 100% of the patient population developed neutropenia, characterized by an absolute neutrophil count (ANC) of 0.0 × 10⁹/L and gastrointestinal (GI) symptoms, including diarrhea. Patients who received the BEAM conditioning regimen developed absolute neutropenia earlier than those who received different conditioning regimens. Twenty (60%) patients developed neutropenic infections confirmed by positive microbiology results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.